FR2492258A1
(fr)
|
1980-10-17 |
1982-04-23 |
Pharmindustrie |
Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
|
EP0154316B1
(en)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified lymphokine and production thereof
|
GB8504025D0
(en)
|
1985-02-16 |
1985-03-20 |
Biopharm Ltd |
Hyaluronidase
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
US4766106A
(en)
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
AU7873187A
(en)
|
1986-08-08 |
1988-02-24 |
University Of Minnesota |
Method of culturing leukocytes
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
US5601819A
(en)
|
1988-08-11 |
1997-02-11 |
The General Hospital Corporation |
Bispecific antibodies for selective immune regulation and for selective immune cell binding
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
US7479269B2
(en)
|
1988-11-23 |
2009-01-20 |
Genetics Institute, Llc |
Methods for selectively enriching TH1 and TH2 cells
|
ATE135370T1
(de)
|
1988-12-22 |
1996-03-15 |
Kirin Amgen Inc |
Chemisch modifizierte granulocytenkolonie erregender faktor
|
DE68929551T2
(de)
|
1988-12-23 |
2008-03-06 |
Genentech, Inc., South San Francisco |
Menschliche DNase
|
US5089261A
(en)
|
1989-01-23 |
1992-02-18 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
US4902502A
(en)
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5126132A
(en)
|
1989-08-21 |
1992-06-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Tumor infiltrating lymphocytes as a treatment modality for human cancer
|
US5177017A
(en)
|
1990-03-22 |
1993-01-05 |
Trigen, Inc. |
Molecular cloning of the genes responsible for collagenase production from Clostridium histolyticum
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
GB9014932D0
(en)
|
1990-07-05 |
1990-08-22 |
Celltech Ltd |
Recombinant dna product and method
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
DK1136556T3
(da)
|
1991-11-25 |
2005-10-03 |
Enzon Inc |
Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
|
JPH05244982A
(ja)
|
1991-12-06 |
1993-09-24 |
Sumitomo Chem Co Ltd |
擬人化b−b10
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US5279823A
(en)
|
1992-06-08 |
1994-01-18 |
Genentech, Inc. |
Purified forms of DNASE
|
DK0672141T3
(da)
|
1992-10-23 |
2003-06-10 |
Immunex Corp |
Fremgangsmåder til fremstilling af opløselige, oligomere proteiner
|
US5593877A
(en)
|
1993-03-11 |
1997-01-14 |
The Rockefeller University |
Nucleic acid and recombinant production of vespid venom hyaluronidase
|
US5422261A
(en)
|
1993-04-16 |
1995-06-06 |
Baxter International Inc. |
Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells
|
JPH08509606A
(ja)
|
1993-04-20 |
1996-10-15 |
ロビンソン,ウィリアム エス. |
細胞内感染因子に感染した個体を処置する方法および物質
|
AU6827094A
(en)
*
|
1993-05-07 |
1994-12-12 |
Immunex Corporation |
Cytokine designated 4-1bb ligand and human receptor that binds thereto
|
GB9317380D0
(en)
|
1993-08-20 |
1993-10-06 |
Therexsys Ltd |
Transfection process
|
US5821332A
(en)
|
1993-11-03 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor on the surface of activated CD4+ T-cells: ACT-4
|
US6989434B1
(en)
|
1994-02-11 |
2006-01-24 |
Invitrogen Corporation |
Reagents for intracellular delivery of macromolecules
|
US5691188A
(en)
|
1994-02-14 |
1997-11-25 |
American Cyanamid Company |
Transformed yeast cells expressing heterologous G-protein coupled receptor
|
DE4447484C2
(de)
|
1994-04-08 |
1997-07-17 |
Deutsches Krebsforsch |
Mittel zur Hemmung von Apoptose
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
CA2193954A1
(en)
|
1994-06-27 |
1996-01-04 |
Vu L. Truong |
Targeted gene delivery system
|
US5908635A
(en)
|
1994-08-05 |
1999-06-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method for the liposomal delivery of nucleic acids
|
US5827642A
(en)
|
1994-08-31 |
1998-10-27 |
Fred Hutchinson Cancer Research Center |
Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
|
US5484720A
(en)
|
1994-09-08 |
1996-01-16 |
Genentech, Inc. |
Methods for calcium phosphate transfection
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
US5830430A
(en)
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
WO1996032495A1
(en)
|
1995-04-08 |
1996-10-17 |
Lg Chemicals Ltd. |
Monoclonal antibody specific for human 4-1bb and cell line producing same
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
US5989888A
(en)
|
1996-01-24 |
1999-11-23 |
Roche Diagnostics Corporation |
Purified mixture of collagenase I, collagenase II and two other proteases
|
US6391607B1
(en)
|
1996-06-14 |
2002-05-21 |
Genentech, Inc. |
Human DNase I hyperactive variants
|
CA2262405A1
(en)
|
1996-08-02 |
1998-02-12 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
JP2001500015A
(ja)
|
1996-09-06 |
2001-01-09 |
トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
T7ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法
|
JP2001502325A
(ja)
|
1996-10-11 |
2001-02-20 |
ブリストル―マイヤーズ・スクイブ・カンパニー |
免疫調整の方法および組成物
|
US6123938A
(en)
|
1996-10-17 |
2000-09-26 |
The Regents Of The University Of California |
Human urinary hyaluronidase
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
US6489458B2
(en)
|
1997-03-11 |
2002-12-03 |
Regents Of The University Of Minnesota |
DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
|
US7118742B2
(en)
|
1997-07-07 |
2006-10-10 |
La Jolla Institute For Allergy And Immunology |
Ligand for herpes simplex virus entry mediator and methods of use
|
US6475994B2
(en)
|
1998-01-07 |
2002-11-05 |
Donald A. Tomalia |
Method and articles for transfection of genetic material
|
CA2321161C
(en)
|
1998-02-24 |
2011-12-20 |
Andrew D. Weinberg |
Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
|
US6312700B1
(en)
|
1998-02-24 |
2001-11-06 |
Andrew D. Weinberg |
Method for enhancing an antigen specific immune response with OX-40L
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
EP1068241B1
(en)
|
1998-04-02 |
2007-10-10 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
PT1071700E
(pt)
|
1998-04-20 |
2010-04-23 |
Glycart Biotechnology Ag |
Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
CA2341029A1
(en)
|
1998-08-17 |
2000-02-24 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
KR100940380B1
(ko)
|
1999-01-15 |
2010-02-02 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
ES2571230T3
(es)
|
1999-04-09 |
2016-05-24 |
Kyowa Hakko Kirin Co Ltd |
Procedimiento para controlar la actividad de una molécula inmunofuncional
|
JP2003502287A
(ja)
*
|
1999-05-20 |
2003-01-21 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
腫瘍壊死因子レセプター5
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
US7189705B2
(en)
|
2000-04-20 |
2007-03-13 |
The University Of British Columbia |
Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
|
AUPQ755300A0
(en)
*
|
2000-05-17 |
2000-06-08 |
Monash University |
Immune potentiating compositions
|
US6627442B1
(en)
|
2000-08-31 |
2003-09-30 |
Virxsys Corporation |
Methods for stable transduction of cells with hiv-derived viral vectors
|
US6706289B2
(en)
|
2000-10-31 |
2004-03-16 |
Pr Pharmaceuticals, Inc. |
Methods and compositions for enhanced delivery of bioactive molecules
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
ES2649037T3
(es)
|
2000-12-12 |
2018-01-09 |
Medimmune, Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
AU2002337935B2
(en)
|
2001-10-25 |
2008-05-01 |
Genentech, Inc. |
Glycoprotein compositions
|
AU2003202908A1
(en)
*
|
2002-01-03 |
2003-07-24 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of t-cells using an engineered multivalent signaling platform
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
EP1487879B1
(en)
|
2002-03-01 |
2012-12-26 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
CN102911987B
(zh)
|
2002-04-09 |
2015-09-30 |
协和发酵麒麟株式会社 |
基因组被修饰的细胞
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
DE60317677T2
(de)
|
2002-06-13 |
2008-10-30 |
Crucell Holland B.V. |
Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
|
US20050084967A1
(en)
|
2002-06-28 |
2005-04-21 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
JP2006506987A
(ja)
|
2002-06-28 |
2006-03-02 |
エクサイト セラピーズ インコーポレーティッド |
自己免疫および臓器または造血幹細胞移植に関連する免疫学的欠損を有する患者における免疫レパートリー回復のための組成物および方法
|
PL375144A1
(en)
|
2002-07-30 |
2005-11-28 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1bb
|
CA2495251C
(en)
|
2002-08-14 |
2018-03-06 |
Macrogenics, Inc. |
Fc.gamma.riib-specific antibodies and methods of use thereof
|
AU2003265948B8
(en)
|
2002-09-06 |
2009-09-03 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
|
DK2345671T3
(en)
|
2002-09-27 |
2016-02-15 |
Xencor Inc |
Optimized Fc variants and methods for their formation
|
NZ539225A
(en)
|
2002-10-09 |
2006-09-29 |
Avidex Ltd |
Single chain recombinant T cell receptors
|
SI1562972T1
(sl)
|
2002-10-15 |
2010-12-31 |
Facet Biotech Corp |
ALTERACIJA FcRn VEZANIH AFINITET ALI SERUMSKIH RAZPOLOVNIH DOB ANTITELESC Z MUTAGENEZO
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
JP4464395B2
(ja)
|
2003-03-05 |
2010-05-19 |
ヘイローザイム インコーポレイテッド |
可溶性ヒアルロニダーゼ糖タンパク質(sHASEGP)、その調製プロセス、使用およびそれを含む薬学的組成物
|
EP3943591A1
(en)
|
2003-10-08 |
2022-01-26 |
Wilson Wolf Manufacturing Corporation |
Cell culture methods and devices utilizing gas permeable materials
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
ATE437184T1
(de)
|
2004-01-12 |
2009-08-15 |
Applied Molecular Evolution |
Varianten der fc-region
|
US20050177518A1
(en)
|
2004-02-10 |
2005-08-11 |
Brown Collie D. |
Electronic funds transfer and electronic bill receipt and payment system
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
DE102004014983A1
(de)
|
2004-03-26 |
2005-10-20 |
Univ Stuttgart |
Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
EP1765860B1
(en)
|
2004-05-19 |
2008-12-10 |
MediGene Ltd. |
High affinity ny-eso t cell receptor
|
EP2295588B1
(en)
|
2004-05-27 |
2018-03-07 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses thefor
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
EP1919950A1
(en)
|
2004-07-15 |
2008-05-14 |
Xencor, Inc. |
Optimized fc variants
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
EP1814568A4
(en)
|
2004-10-29 |
2009-08-12 |
Univ Southern California |
ANTI-CANCER POLYIMMUNOTHERAPY IN WHICH CO-STIMULATING MOLECULES ARE USED
|
DK2343320T3
(da)
|
2005-03-25 |
2018-01-29 |
Gitr Inc |
Anti-gitr-antistoffer og anvendelser deraf
|
EP2650020B1
(en)
|
2005-05-06 |
2016-08-24 |
Providence Health & Services - Oregon |
Trimeric OX40-immunoglobulin fusion protein and methods of use
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
SI1907424T1
(sl)
|
2005-07-01 |
2015-12-31 |
E. R. Squibb & Sons, L.L.C. |
Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
|
US8007785B2
(en)
|
2005-12-21 |
2011-08-30 |
Sentoclone International Ab |
Method for treating colon cancer with tumour-reactive T-lymphocytes
|
RU2399382C2
(ru)
|
2005-12-21 |
2010-09-20 |
Сентоклон Аб |
Улучшенный способ увеличения числа опухоле-реактивных т-лимфоцитов в иммунотерапии онкологических больных
|
AU2006328944B2
(en)
|
2005-12-21 |
2011-08-25 |
Sentoclone International Ab |
Method for treating disseminated cancer
|
AU2006328945B2
(en)
|
2005-12-21 |
2011-06-30 |
Sentoclone International Ab |
Method for treating malignant melanoma
|
US7596024B2
(en)
|
2006-07-14 |
2009-09-29 |
Semiconductor Energy Laboratory Co., Ltd. |
Nonvolatile memory
|
EP1894940A1
(en)
|
2006-08-28 |
2008-03-05 |
Apogenix GmbH |
TNF superfamily fusion proteins
|
EP1914242A1
(en)
*
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
RU2009135824A
(ru)
|
2007-02-27 |
2011-04-10 |
Дженентек, Инк. (Us) |
Антитела-антагонисты против ох40 и их применение в лечении воспалительных и аутоиммунных заболеваний
|
AU2008266951B2
(en)
|
2007-06-18 |
2013-12-12 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor PD-1
|
US7951365B2
(en)
|
2007-06-27 |
2011-05-31 |
Deifiera Falun Ab |
Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
|
EP3072903B1
(en)
|
2007-07-10 |
2017-10-25 |
Apogenix AG |
Tnf superfamily collectin fusion proteins
|
US20090028857A1
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
EP3239178A1
(en)
|
2007-12-14 |
2017-11-01 |
Bristol-Myers Squibb Company |
Binding molecules to the human ox40 receptor
|
WO2009094273A2
(en)
*
|
2008-01-15 |
2009-07-30 |
Yale University |
Compositions and methods for adoptive and active immunotherapy
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
EP2540740B1
(en)
|
2008-06-17 |
2014-09-10 |
Apogenix GmbH |
Multimeric TNF receptors
|
PT2310509E
(pt)
|
2008-07-21 |
2015-05-19 |
Apogenix Gmbh |
Moléculas de tnfsf em cadeia simples
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
US20150320798A1
(en)
|
2012-11-27 |
2015-11-12 |
The Johns Hopkins University |
Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunity
|
CN108997498A
(zh)
|
2008-12-09 |
2018-12-14 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
JP5844158B2
(ja)
|
2009-01-09 |
2016-01-13 |
アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングApogenix GmbH |
三量体形成融合タンパク質
|
US8785601B2
(en)
*
|
2009-01-28 |
2014-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
AU2010241864B2
(en)
|
2009-04-30 |
2014-02-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inducible interleukin-12
|
US8383099B2
(en)
|
2009-08-28 |
2013-02-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adoptive cell therapy with young T cells
|
LT3023438T
(lt)
|
2009-09-03 |
2020-05-11 |
Merck Sharp & Dohme Corp. |
Anti-gitr antikūnai
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
US20130115617A1
(en)
|
2009-12-08 |
2013-05-09 |
John R. Wilson |
Methods of cell culture for adoptive cell therapy
|
JP2013512694A
(ja)
|
2009-12-08 |
2013-04-18 |
ウィルソン ウォルフ マニュファクチャリング コーポレイション |
養子細胞療法のための細胞を培養する方法
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
EA024701B1
(ru)
|
2010-04-13 |
2016-10-31 |
Селлдекс Терапьютикс Инк. |
Антитела, связывающие cd27 человека, и их применение
|
US9783578B2
(en)
|
2010-06-25 |
2017-10-10 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
WO2012004367A1
(en)
|
2010-07-09 |
2012-01-12 |
N.V. Organon |
Agonistic antibody to cd27
|
PT2609118T
(pt)
|
2010-08-23 |
2017-03-22 |
Univ Texas |
Anticorpos anti-ox40 e métodos de utilização dos mesmos
|
RU2710717C2
(ru)
|
2010-09-09 |
2020-01-10 |
Пфайзер Инк. |
Молекулы, связывающиеся с 4-1ВВ
|
ES2385239B1
(es)
|
2010-09-30 |
2013-06-19 |
Proteos Biotech S.L.U. |
Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno.
|
US8962804B2
(en)
|
2010-10-08 |
2015-02-24 |
City Of Hope |
Meditopes and meditope-binding antibodies and uses thereof
|
HUE054318T2
(hu)
|
2010-11-12 |
2021-08-30 |
Nektar Therapeutics |
IL-2 molekularész konjugátumai és polimer
|
KR20230133410A
(ko)
|
2010-12-09 |
2023-09-19 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도
|
WO2012129201A1
(en)
|
2011-03-22 |
2012-09-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
|
CN103502439B
(zh)
|
2011-04-13 |
2016-10-12 |
因缪尼卡姆股份公司 |
用于抗原特异性t细胞增殖的方法
|
EP2717895A1
(en)
|
2011-06-08 |
2014-04-16 |
Aurigene Discovery Technologies Limited |
Therapeutic compounds for immunomodulation
|
WO2012177788A1
(en)
|
2011-06-20 |
2012-12-27 |
La Jolla Institute For Allergy And Immunology |
Modulators of 4-1bb and immune responses
|
WO2013014668A1
(en)
|
2011-07-24 |
2013-01-31 |
Curetech Ltd. |
Variants of humanized immunomodulatory monoclonal antibodies
|
EP2748199B1
(en)
|
2011-08-23 |
2019-08-28 |
Board of Regents, The University of Texas System |
Anti-ox40 antibodies and methods of using the same
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
EP2756521A4
(en)
|
2011-09-16 |
2015-04-22 |
Univ Pennsylvania |
RNA-MANIPULATED T-CELLS FOR THE TREATMENT OF CANCER
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
AU2012324644B2
(en)
|
2011-10-21 |
2014-08-28 |
Cell Medica Limited |
Device for the aseptic expansion of cells
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-pd-l1 항체 및 그의 용도
|
GB201121308D0
(en)
|
2011-12-12 |
2012-01-25 |
Cell Medica Ltd |
Process
|
WO2013132317A1
(en)
|
2012-03-07 |
2013-09-12 |
Aurigene Discovery Technologies Limited |
Peptidomimetic compounds as immunomodulators
|
AU2013239366A1
(en)
|
2012-03-29 |
2014-10-16 |
Aurigene Discovery Technologies Limited |
Immunomodulating cyclic compounds from the BC loop of human PD1
|
CN104379727A
(zh)
|
2012-05-18 |
2015-02-25 |
威尔逊沃夫制造公司 |
改进的用于过继细胞治疗的细胞培养方法
|
CN110241086A
(zh)
|
2012-06-11 |
2019-09-17 |
威尔逊沃夫制造公司 |
用于过继细胞疗法的改进的细胞培养方法
|
DK2925329T3
(da)
|
2012-11-27 |
2021-03-22 |
Ivan Marques Borrello |
Anvendelse af cyclophosphamid-behandlede knoglemarvsinfiltrerende lymfocytter efter transplantationer til øgning af antitumorimmunitet
|
CA2902448C
(en)
|
2013-03-01 |
2023-04-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing enriched populations of tumor reactive t cells from peripheral blood
|
EP2961415B1
(en)
|
2013-03-01 |
2021-01-06 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Methods of producing enriched populations of tumor-reactive t cells from tumor
|
MX2015012920A
(es)
|
2013-03-14 |
2016-06-02 |
Univ Johns Hopkins |
Celulas presentadoras de antígeno artificial de nanoescala.
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
BR112015023862A2
(pt)
|
2013-03-18 |
2017-10-24 |
Biocerox Prod Bv |
anticorpo isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira, método de realçar uma resposta imune, método de tratar câncer, composição farmacêutica, e, anticorpo agonístico isolado
|
EP3004320A4
(en)
|
2013-06-24 |
2017-05-17 |
Wilson Wolf Manufacturing Corporation |
Closed system device and methods for gas permeable cell culture process
|
GB201311487D0
(en)
*
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Bispecific molecules
|
RU2713333C2
(ru)
|
2013-07-15 |
2020-02-04 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Способы получения т-клеток против антигена папилломавируса человека
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
SG11201601679TA
(en)
|
2013-09-06 |
2016-04-28 |
Aurigene Discovery Tech Ltd |
1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
|
ES2788848T3
(es)
|
2013-09-06 |
2020-10-23 |
Aurigene Discovery Tech Ltd |
Derivados de 1,2,4-oxadiazol como inmunomoduladores
|
WO2015036927A1
(en)
|
2013-09-10 |
2015-03-19 |
Aurigene Discovery Technologies Limited |
Immunomodulating peptidomimetic derivatives
|
SG11201601844TA
(en)
|
2013-09-13 |
2016-04-28 |
Beigene Ltd |
Anti-pd1 antibodies and their use as therapeutics and diagnostics
|
WO2015039100A1
(en)
|
2013-09-16 |
2015-03-19 |
The Trustees Of The University Of Pennsylvania |
Cd137 enrichment for efficient tumor infiltrating lymphocyte selection
|
EP3048999A1
(en)
|
2013-09-27 |
2016-08-03 |
Acclarent, Inc. |
Enhanced gripping features for nasal and paranasal sinus systems
|
EP3060059A4
(en)
*
|
2013-10-25 |
2017-11-01 |
Board of Regents, The University of Texas System |
Polyclonal gamma delta t cells for immunotherapy
|
EP3083687A2
(en)
|
2013-12-17 |
2016-10-26 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
ES2783026T3
(es)
|
2014-02-04 |
2020-09-16 |
Pfizer |
Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer
|
MX2016012176A
(es)
|
2014-03-20 |
2017-04-13 |
H Lee Moffitt Cancer Ct & Res |
Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
|
EP3154350B1
(en)
|
2014-04-10 |
2024-03-27 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
|
US11173146B2
(en)
|
2014-04-25 |
2021-11-16 |
The Regents Of The University Of California |
Selective activators of the intermediate conductance CA2+activated K+ channel KCa3.1 and their methods of use
|
CA2953277A1
(en)
*
|
2014-06-05 |
2015-12-10 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Means and methods for determining t cell recognition
|
CN106574244B
(zh)
|
2014-06-11 |
2022-01-07 |
保利比奥斯博特有限责任公司 |
用细胞因子组合物扩增淋巴细胞用于主动细胞免疫治疗
|
CA2959994C
(en)
|
2014-09-04 |
2023-04-11 |
The Johns Hopkins University |
Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
|
CN107074932A
(zh)
|
2014-10-02 |
2017-08-18 |
美国卫生和人力服务部 |
分离对癌症特异性突变具有抗原特异性的t细胞受体的方法
|
EP3034092A1
(en)
|
2014-12-17 |
2016-06-22 |
Université de Lausanne |
Adoptive immunotherapy for treating cancer
|
EP3240896A1
(en)
|
2015-01-04 |
2017-11-08 |
Protalix Ltd. |
Modified dnase and uses thereof
|
WO2016145085A2
(en)
|
2015-03-09 |
2016-09-15 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
CA2984234C
(en)
|
2015-05-01 |
2023-10-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
|
FR3038324B1
(fr)
|
2015-06-30 |
2020-10-30 |
Lab Francais Du Fractionnement |
Procede de cryoconservation de cellules a visee therapeutique
|
FR3040396A1
(fr)
|
2015-06-30 |
2017-03-03 |
Chu Nantes |
Procede de cryoconservation de lymphocytes infiltrant la tumeur
|
WO2017048614A1
(en)
|
2015-09-15 |
2017-03-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
CA3003334A1
(en)
|
2015-10-28 |
2017-05-04 |
Life Technologies As |
Selective expansion of different subpopulations of t cells by the alteration of cell surfacing signals and signal ratio
|
WO2018005712A1
(en)
|
2016-06-28 |
2018-01-04 |
Geneius Biotechnology, Inc. |
T cell compositions for immunotherapy
|
CN106244538A
(zh)
|
2016-08-04 |
2016-12-21 |
英普乐孚生物技术(上海)有限公司 |
一种恶性腹水来源的til细胞的分离培养方法
|
BR112019008305A2
(pt)
|
2016-10-26 |
2019-08-06 |
Iovance Biotherapeutics Inc |
métodos para expansão de linfócitos infiltrantes de tumor, para avaliação da atividade metabólica de uma população de células til, para tratamento de um sujeito com câncer e para ensaiar tils, e, população de tils expandidos
|
US20200095547A1
(en)
|
2016-12-02 |
2020-03-26 |
Darya ALIZADEH |
Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
|
CN106591232A
(zh)
|
2017-01-04 |
2017-04-26 |
安徽安龙基因医学检验所有限公司 |
一种高效的pd‑1‑cd8+t细胞的培养方法
|
AU2018234640B2
(en)
|
2017-03-14 |
2024-03-14 |
Juno Therapeutics, Inc. |
Methods for cryogenic storage
|
CN107384867B
(zh)
|
2017-08-04 |
2020-09-11 |
北京世纪劲得生物技术有限公司 |
一种肿瘤组织til细胞制备方法及专用培养基
|